Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcellaâs AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcellaâs AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering. Source
No articles found.
Eagle is a specialty pharmaceutical company working to advance safe and efficient ...
Eagle is a specialty pharmaceutical company wor...
Luna (NASDAQ:LUNA) develops and manufactures new-generation products for the healt...
Luna (NASDAQ:LUNA) develops and manufactures ne...
Founded in 2006 and headquartered in San Diego, Adamis (ADMP) is a specialty bioph...
Founded in 2006 and headquartered in San Diego,...
BrainsWay is an industry leader in the field of transcranial magnetic stimulation ...
BrainsWay is an industry leader in the field of...
Join the National Investor Network and get the latest information with your interests in mind.